Swiss National Bank increased its stake in Catalent Inc (NYSE:CTLT) by 2.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 224,570 shares of the company’s stock after purchasing an additional 5,300 shares during the period. Swiss National Bank owned approximately 0.17% of Catalent worth $9,225,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Zions Bancorporation bought a new position in shares of Catalent in the third quarter worth approximately $100,000. First Bank & Trust grew its position in Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after acquiring an additional 1,323 shares during the last quarter. Fortaleza Asset Management Inc. bought a new position in Catalent during the third quarter valued at approximately $164,000. CAPROCK Group Inc. bought a new position in Catalent during the fourth quarter valued at approximately $203,000. Finally, Eagle Boston Investment Management Inc. bought a new position in Catalent during the third quarter valued at approximately $216,000. Institutional investors own 99.82% of the company’s stock.
In other news, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.70% of the company’s stock.
Catalent Inc (CTLT) opened at $42.81 on Thursday. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66. The company has a market capitalization of $5,663.38, a price-to-earnings ratio of 75.11, a price-to-earnings-growth ratio of 2.44 and a beta of 1.47. Catalent Inc has a 52-week low of $27.48 and a 52-week high of $47.87.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, February 5th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The company’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.27 earnings per share. equities research analysts forecast that Catalent Inc will post 1.53 EPS for the current fiscal year.
Several brokerages have recently issued reports on CTLT. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Piper Jaffray Companies raised their target price on shares of Catalent from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, November 7th. First Analysis began coverage on shares of Catalent in a report on Friday, January 5th. They issued an “equal weight” rating on the stock. Finally, Royal Bank of Canada began coverage on shares of Catalent in a report on Wednesday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Catalent has an average rating of “Buy” and an average price target of $45.70.
WARNING: “Catalent Inc (CTLT) Shares Bought by Swiss National Bank” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/02/22/catalent-inc-ctlt-shares-bought-by-swiss-national-bank.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.